Our data have shown that the UPI peptide can efficiently attenuate prostate cancer progression in Tramp mouse models and glioma mouse models [Figure 9A and B].[19] Mechanistically, UPI peptide inhibits Epsin-VEGFR2 interaction in vivo and produces non-functional tumor angiogenesis [Figure 9C]. Here, KDR is linked to prostate cancer.